Actual-world therapy with the autologous anti-CD19 CAR T-cell remedy Yescarta (axicabtagene ciloleucel; axi-cel) demonstrated sturdy responses and a manageable security profile amongst...
Remedy with Tecvayli (teclistamab-cqyv) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj; subcutaneous daratumumab) led to significant enhancements in each general survival and progression-free...
Utilizing dexamethasone earlier than remedy was related to much less extreme immune effector cell-associated neurotoxicity syndrome (ICANS) however didn't change how usually...
The 96-week outcomes from the MANIFEST-2 part 3 trial present that including pelabresib to Jakafi (ruxolitinib) can present stronger, clinically significant advantages...
